Janssen Sciences Ireland UC

Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Ad...

Official Title: 
JNJ-53718678 RSV Pre-Approval Access_Single Patient Access (SPR) for Patients Diagnosed With RSV
Brief Summary: 
The purpose of this pre-approval access program is to provide treatment to immunocompromised participants with serious/life-threatening diseases or conditions (Respiratory Syncytial Virus [RSV] infection) and to collect the safety data to understand the safety profile of JNJ-53718678.
Available
EA Type
Individual Patients
Respiratory Syncytial Virus

Drug: JNJ-53718678
JNJ-53718678 will be administered as directed by treating physician.

Contacts: 

Contact
1-800-JANSSEN (1-800-526-7736)
Janssenmedinfo@its.jnj.com

Janssen Research & Development, LLC Clinical Trial
Study Director
Janssen Research & Development, LLC

Janssen Sciences Ireland UC
EA Number: 
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.